No data to show
XNAS
PGNY
Market cap1.95bUSD
Apr 28, Last price
23.00USD
1D
-0.04%
1Q
-3.56%
IPO
32.19%
Name
Progyny Inc
Chart & Performance
P/E
36.26
P/S
1.69
EPS
0.63
Div Yield, %
—
Shrs. gr., 5y
2.69%
Rev. gr., 5y
38.42%
Revenues
1.17b
+7.22%
Net income
54m
-12.41%
CFO
179m
-5.14%
Earnings
May 07, 2025
Profile
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 1,167,221 7.22% | 1,088,598 38.34% | 786,913 57.19% | |||||
Cost of revenue | 1,099,766 | 1,026,414 | 763,572 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 67,455 | 62,184 | 23,341 | |||||
NOPBT Margin | 5.78% | 5.71% | 2.97% | |||||
Operating Taxes | 28,866 | 8,654 | (5,917) | |||||
Tax Rate | 42.79% | 13.92% | ||||||
NOPAT | 38,589 | 53,530 | 29,258 | |||||
Net income | 54,336 -12.41% | 62,037 104.35% | 30,358 -53.84% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (300,278) | (11,072) | (9,016) | |||||
BB yield | 18.24% | 0.30% | 0.29% | |||||
| Debt | ||||||||
Debt current | 2,859 | 2,149 | 1,231 | |||||
Long-term debt | 35,685 | 36,631 | 12,964 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | (3,016) | |||||||
Net debt | (189,410) | (332,307) | (175,105) | |||||
| Cash flow | ||||||||
Cash from operating activities | 179,105 | 188,814 | 80,395 | |||||
CAPEX | (5,405) | (3,644) | (3,241) | |||||
Cash from investing activities | 195,792 | (200,525) | (43,866) | |||||
Cash from financing activities | (309,880) | (11,072) | (7,864) | |||||
FCF | 43,293 | 41,718 | (17,907) | |||||
| Balance | ||||||||
Cash | 227,954 | 371,087 | 189,300 | |||||
Long term investments | ||||||||
Excess cash | 169,593 | 316,657 | 149,954 | |||||
Stockholders' equity | 48 | 92,799 | 28,444 | |||||
Invested Capital | 441,286 | 480,020 | 353,221 | |||||
ROIC | 8.38% | 12.85% | 9.50% | |||||
ROCE | 15.28% | 10.86% | 6.07% | |||||
| EV | ||||||||
Common stock shares outstanding | 95,448 | 100,672 | 99,957 | |||||
Price | 17.25 -53.60% | 37.18 19.36% | 31.15 -38.13% | |||||
Market cap | 1,646,484 -56.01% | 3,743,000 20.21% | 3,113,666 -38.38% | |||||
EV | 1,457,074 | 3,410,693 | 2,938,561 | |||||
EBITDA | 70,630 | 64,465 | 24,942 | |||||
EV/EBITDA | 20.63 | 52.91 | 117.82 | |||||
Interest | 814 | |||||||
Interest/NOPBT | 3.49% | |||||||